Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Capacity Utilization - Capsules % ・Standalone data |
|
||||||||
| Capacity Utilization - Tablets % ・Standalone data |
|||||||||
| Installed Production Capacity - Capsules Million units/month ・Standalone data |
|||||||||
| Installed Production Capacity - Dry Syrup MT/month ・Standalone data |
|||||||||
| Installed Production Capacity - Tablets Million units/month ・Standalone data |
|||||||||
| Geography-wise Revenue Diversification (Overseas Market) % ・Standalone data |
|||||||||
| Capacity Utilization - Dry Syrup % ・Standalone data |
|||||||||
| Total Products in Portfolio Number of Products ・Standalone data |
|||||||||
| Number of Manufacturing Units Count ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Audited Standalone Financial Results Of The Company For The Quarter Ended 31St March, 2026 And Audited Financial Statements For The Year Ended On 31St March, 2026 Along With The Auditor'S Report Thereon
21 May - Board approved FY26 audited standalone results; unmodified audit opinion, meeting held 21 May 2026.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
21 May - Medico Remedies confirms it is not a Large Corporate; outstanding borrowing was INR 0.35 crore on March 31, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today
21 May - Board approved audited FY26 standalone results; revenue Rs 206.38 crore, net profit Rs 3.12 crore, unmodified opinion.
-
Board Meeting Intimation for Meeting Of The Board Of The Company To Be Held On Thursday, 21St May 2026,
15 May - Board meeting on 21 May 2026 to approve Q4 FY26 and annual audited results.
-
Intimation Of Action Taken Or Order Passed By Regulatory,
Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations')
16 Apr - NSE and BSE levied Rs. 63,720 each for Regulation 6(1) non-compliance; waiver rejected, fines paid.
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments